Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Connect Biopharmaceuticals
Biotech
Connect’s Dupixent rival hits the mark in phase 3 eczema trial
Connect reported 52-week improvements across multiple endpoints, fueling the biotech’s belief that its molecule is better than Dupixent.
Nick Paul Taylor
Mar 30, 2026 9:32am
Connect reduces China workforce, mulls strategy for asthma drug
Sep 6, 2024 4:37am
J&J, Bayer, Santa Ana, Regenxbio and more—Chutes & Ladders
Jun 14, 2024 8:30am
Connect uncouples from Pfizer by scrapping eczema pact
Apr 17, 2024 6:38am
Connect blames 'challenging environment' for lead program pause
Jan 3, 2023 7:55am
Chasing BMS and Pfizer, Connect fails ulcerative colitis trial
May 4, 2022 7:53am
